FDG PET/MRI 診療ガイドライン 2012 Ver 1.0
Contents
1.2. 4
3. 8 MRI RE MRI
4. PET MRI MRI
5. 1 1 1 78 2
6. E ZIEL PET MRIT MR PET MRI MRI
7. gt 68 JIS Z 4951 0 5mT 5 Gauss lt MRI gt 2 lt gt HE 2
8. 66 4 E
9. EA WEEK 2 4 3 Hituximab 3 FDG
10. FDG PET 90 SPECT D e 2 9 PET MRI PET MRI 3 3
11. 98 W 5 2
12. MRI MRI
13. 1 2 fal 3 4 5 E
14. 1 2 3 4 5
15. FDG 4 1 Keyes JW Jr et al Salivary gland tumors pretherapy evaluation with PET Radiology 1994 192 99 102 2 Kwak JY et al Thyroid incidentalomas identified by 8F FDG PET sonographic uu iH E i Ea
16. MET ONREG AD FTD Medicare FDG PET 47 A O 1 pU ds d Ga MM H MCI 8i A VERE PET MR PET MRI
17. 1 PET MRI 1 1 PET PET FDG PET 1 2 MRI 24 MRI 24 6 1 JIS Z 4951 2012 ERE IC MRI
18. 81 1 MRI 2 3
19. 92 1 PET MRI MRI PET MRI MRI MRI PET PET MRI D MRI MRI PET MRI PET MRI MRI PET
20. 2 A SEC phased array coil 2 T2 T1 MR spectroscopy R T RES DRE SCA ACA Bic TI T2 70 T1 Rad ZO in phase out of phase Vd WES CI MR
21. MM EON RA 3 67 1
22. FDGPET CT 2 PET HZ 0 Wee bbe Cc OPE A MO PET P ICV no EKBSET HE 23 Al 4 MRI FZT MRI Tit IEY J 0 1 1
23. RF 1 2 3 A 5 6 7 8 4
24. 2 MRI MRI FDG 1 lcd Y ees FDG PET CT MRI MR d PET MRI PET MRI MRI PET ee HE 1 ARTE YRD RARR F E 38 x 1 f CT GES IUTVYD PET MRI
25. IE fe SREB A E RAR ee Za pf c pii RES IC LY 3 ZEE QE 7 De ix ERTI B 1 3 250 pSv
26. 79 PET CT PRT MRI 2 OFDG 2D 185 444MBq 3 7MBq kg 3D 111 259MBq 2 5MBq kg FDG RE 40 60 PET MRI MRI MRI 8g
27. CT PET CT PET CT MRI CT PET MRI OT E MRI
28. PET PET 30 RO 18 2 f ik 3 SEA 5mSv 9 TE 2
29. ol PET MRI MRI PET MRI MRI MR PET MRI MRI MRI MRI PET MRI MRI PET
30. FDG 4 1 Kwee TC et al FDG PET CT in carcinoma of unknown primary Eur J Nucl Med Mol Imaging 2010 37 635 644 2 Takahara T et al Diffusion weighted whole body imaging with background body signal suppression DWIBS technical improvement using free breathing STIR and high resolution 3D display Radiat Med 2004 22 275 282 3 Kubota K et al Advantage of delayed whole body FDG PET imaging for tumour detection Eur J Nucl Med 2001 28 696 703 46 gu IV l FDG PET AD OF AD FDG PET 2004
31. 1 2 FDG PET 1 8 1 FDG PET 2 1 CBE 52 BR OT
32. 3 1 2 2 JE as EL A AAW Ac dx 2 s NA 1 LERET JZ CLES BUR ORET 2 RT 3 3 WOES ABE E A
33. NA 4 70 ED E V E E
34. ik 4 ICRP Publication 60 991 10 7 FDG PET FDG PET 7 1 55 aN E FT PRI HH Be ez 1 30 FDG 2 ERU EE PDG WE PET AD 8 2
35. V HIC G8E n 7 2 DFDG PET 4 PET CT 76 2 PET MRI F FDG 2D 185 444MB q 3 7MBq kg 3D 111 259MBq 2 5MBq kg FDG Eun 10 PET du ARG
36. Rituximab 10 T 4 amp 5 12 y a FDG b 60 c JUS V 4 2D 185 444MBq 3 7MBq kg 3D 2 5MBq kg FDG PET MRI E FDG 111 259MBq Hi
37. 0 5mT 5 Gauss MRI MRI amp 7 MRI 8 hee 9 MRI NN BE LOO T E ff Wi jk 10 64 11 12
38. 30 27 PET 1 6 mSv FDG 1 5mSv PET 3 5 2 2 PET PET FDG FDG
39. Wu S amp iy I 18R 2 2 D FDG PET 14 4 12 dod Hes SLI en WEE His MEARE ed FDG PET 17 E FDG TEMO 3 PET CT PET CT
40. 5 2 5 FDG aN X D H re j s a 5 2 6 PET PET n MSE 5 2 7 PET 400 500 MBq 4 E
41. PET MRI mg PET MRI FDG PET PET CT 2010 2012 KF http www jsnm org guideline 20100330 FDG PET MRI ue H E 4 E JMRI PET PA
42. 30 AO 26 1 FDG 9 FDG FDG 9 1 FDG FDG Jc RR 18 1 18 10 30 10 i 16 H 56 4 58 F5 9 2 FDG FDG OU I
43. gt MR gt RMERGENCY STOP lt gt MRI
44. u i gt B 1 2 PET MRI PET MRI 80 8 2 MRI JIS Z 4951 2012 PET 1 2 PET MRI PET PET
45. 2 2 79 1 La amp sm exs ueaa rasa 7 ra a b O Er 5 0 m Rt ut RSEN smmawmaazrs o E e GRAN f RAEN OD eR FEBR lt g LC enson se o Dwsmroowm oh o bmwswe f EET Aion WmaEsum O wmm wxosw amp mwaesam o ak 1 9 L Se
46. 4 82 4 ee 3 m av MRI
47. A WIA A Ae es Ly EIS 74 A 75 5
48. TE MRI MRI 1 2 TDA 8T 62 2 RF radio frequency RF vV
49. TI LET 72 MR EA FICA ON Fy PA Hk
50. 6 BAK i 4i 1 FDG 2 FDG 2 4 D ERO 10 ERMO 3 FDG PET 4 FDG PET BA
51. MR transmission wb cor O O O T1WI wb cor O O O STIR wb cor O O T2WI spine sag O O DWI wb ax O O O Gd T1WI wb cor O T1WI DB chest ax O O STIR DB chest ax o o A DCE chest cor O Gd T1WI1 chest ax O PET wb ax o O O PET delay chest ax wb whole body ax axial cor coronal sag sagittal 3 PET MRI susceptibility STIR ME BLISODC iE Cc OS C HERIS VE C S A 1 Schwenzer NF et al Pulmonary Lesion Assessment Comparison of Whole Body Hybrid MR PET and PET CT Imaging Pilot Study Radiology 2012 264 551 558 2 Bruzzi JF et al Imagi
52. 1 2 PET eae 3 ZE 4 PET 5 3 E eps 28 1 5 29 2 NN DF 1 7 FDG inm IH aN CT FDG
53. 2 XX CT MRI AD FDG PET KX I FDG MCI OP 1 1 FDG PET
54. TDG PET 2 2 1 PET 2 3 4 5 6 7 8 PET CT CT PET MRI MR 9 2D 3D 10 11 12 13 14 15 Ri FJIR il 51 FDG PET 2
55. Tie W 73 Tn MR WE ZZ ER
56. 1019 PET MRI 2 Whole bodyPET MRI localized PET MRI 3 MRI MR 17 EYE LN field of view FOV T2 RIRA H da am TI
57. upper gastrointestinal malignancies World J Gastroenterol 2011 17 5059 5074 3 6 2 4 1 2012 PET MRI PET MRI v2 MRI PET MRI 3 9 MRI PET MRI 34 2 MRI SE T2 3 1 Smyth EC et al Role of F 2 fluoro 2 deoxyglucose positron emission tomography in
58. 2 MRI
59. 48 16 8 1 0801001 PRI E 1 FLAS Sry FDG RC RZTRI 2 El xz HH dS 1 2 Ey May AS 1 FDG PET
60. 6 700
61. 5 ZW 2 1 gt HARE
62. 25 MRI MRI e SAR r He EZ AB MRI BO Rt PET MRI MRA perfusion MRI Ba rob T bi PRT MRI 2 PET MRI One biti
63. 1 RF 2 77 3 4 5 24 60 6
64. 1 FDG PET 2 FDG PET 3 FDG 4 FDG 5 PET 6 7 8 FDG FDG PET 9 g 3 FDG FDG
65. 49 FDG PET Ck 598 MRI 610 PET CT 2 DPET MRI os osos STIR T2 T1 B uc d c uu perfusion zi gt 21 3 3
66. B JJ IN 7 WS H 1 2 BB oy Uo J yo TES AR Lm
67. FDG PET PET MRI PET ij l 1 2
68. RF RF MRI 4 1
69. 1 2 xm
70. 14 RE cr s 138 5 55 Dn 1 T 65 H pip ft E OIE F
71. E elt TED PET f 1 2 PET 3 FDG 54 FDG FDG 1 E E
72. 3 3 ri 1 ZW EN no Ju 1 1 2
73. 59 1 PET zz PET 2 28 S M 1 5 PET 1 28 1 4
74. PRET MRI 2 PET 3 4 Da
75. 2 MRI K 3 MRIJ te OREO AL MRIj Do
76. ICRP Publication 80 1 9 185 MBq 5 mCi 3 5 mSv 68Ge 68Ga 0 25 mSv PET CT 1 4 8 5 mSv 10 mSv PET MRI H CT E X CT X CT X 1 FDG 52 ot Hill mGy MBq mGy MBq mSv MBq
77. 1 2 3 MRI 4 5 6 te IL E 1 SR OR PET 3
78. 58 PET HB PALS PREITY EFA CID 2 FDG KA PET FDG BR It 5 2 3
79. E E MRI MRI ZS 1 2006 MR 63 MRI 17 4
80. 3D e T2 T2 ds FDG PET 0 myeloid hyperplasia 9 PET CT CT SHA HETS 9 Barrington O Deauville crieteria London criteria reference 9 SD or PD
81. ja mmol kg zz xt at PET MRI 2 BRL RH 23 T 2 2 T 5 7 E 1X1mm 3mm MRI
82. MRI 4 1 Dummer R et al Melanoma ESMO clinicalpractice guidelines for diagnosis treatment and follow up Ann Oncol 2010 21 suppl 5 v194 v197 yay at Hu Bd NHI d 2 Xing Y et al Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients a meta analysis JNatl Cancer Inst 2011 103 129 142 3 Wagner JD et al Prospective study of fluorodeoxyglucose positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy J Clin Oncol 1999 17 1508 1515 4 Wagner JD et al Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma AnnSurg Oncol 1999 6 398 404 5 Horn J et al Routine use of FDG PET scans in melanoma patients with positive sentinel node biopsy Eur J Nucl Med MolImaging 2006 33 887 892 6 Strobel K et al Chemotherapy response assessment in stage IV
83. MRI TI T1 PET T2 19 PET MRI PET MRI PET CT 14 2 MRI T1 9 MRCP 3 1 Low G et al Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas Radiographics 2011 31 993 1015 2 Tatsumi M et al 18F FDG PET MRI fusion in characterizing pancreatic tumors comparison to PET CT Int J Clin Oncol 2011 16 408 415 3 3T MRI ARER 2010 30 190 197 4 Smyth EC et al Role of F 2 fluoro 2 deoxyglucose positron emission tomography in
84. 6cc6383 f 3 EA Bug MRI ulli E 2 SRY yy ee T2 5 12 E PET MRI E MRI ACR BI RADS Breast Imaging Reportingand Data System
85. 3 1 3 mSv 3 1 3 mSv Tif 56 ix PET PET 9 US ECT RH SE CER TE 4 mSv ELV 4 E 100 mSv PET ol x Ny 5 M nz TUB UMORE fi PET 3
86. MR C MRI MRI D MRI E
87. HY DAA BE DS ty 3 Q 1 PET PET CT 2 13N PET S2Rb PET 6 PET TT 1 ACC AHA ASNC Guidelines Circulation 2003 108 1404 1418 2 American Society of Nuclear Cardiology Practice guidelines J Nucl Cardiol 2003 10 543 571 3 Knuuti J et al The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in dysfunction Eur J Nucl Med 2002 29 patients with chronic ischaemic left ventricular 1257 1266 4 Schelbert HR 18F deoxyglucose and the assessment of myocardial viability Semin Nucl Med 2002 32 60 69 3
88. n E gt i yu ac 8 RF 9 RF D O
89. EH IU BEOIR H E avidity MRI OFF E E FDG PET 5 R dg H DLBCL Hja E PET CT 2D 185 444MBq 3 7MBq kg 3D 111 259MBq 2 5MBq kg FDG if 60 2 PET MRI H H Fan 43 j x MRI
90. PET E 2009 29 2 195 235 129 FDG PET iind 4 Z 42 1 26 2005 zi FDG 37 F 7 8 amp 0 C2 18F FDG FDG 24 4
91. ay W upper gastrointestinal malignancies World J Gastroenterol 2011 17 5059 5074 2 Shimada H et al Japanese Gastric Cancer Association Task Force for Research Promotion clinical utility of F fluoro 2 deoxyglucose positron emission tomography in 30 gastric cancer systematic review of the literature Gastric Cancer 2011 14 13 21 3 Basu S et al FDG PET and PET CT in the clinical management of gastrointestinal stromal tumor Nucl Med Commun 2008 29 1026 1039 4 Sandrasegaran K et al Gastrointestinal stromal tumors CT and MRI findings Eur Radiol 2005 15 1407 1414 3 7 MRI 77 1 110 FDG
92. A 2 OFDG 2D 185 444MBq 3 7MBq kg 3D 111 259MBq 2 5MBq kg FDG 60 PRT MRI MRI MRI 8g 1 8D thinslice c T2 T2 c T2 ADC 9 FDG PET MRS
93. m PET MRI 1 PET MRI 5 PET MRI MRI REPE H 2012 8 PY ARR H FDG PET RU MRI H U FDG PET 59 MRI
94. T1 of 2 T2 PET MRI PET MRI MRI
95. 1 ERKA ALARA as low as reasonably achievable DEE B 24 7 FDG FDG FDG FDG PET 1
96. 4 MR i 1 1 1 1 1 1 P ET MRI
97. PET 28 1 7 1 24 7 2 24 8 3 24
98. 7 1 2 3 4 5 6 iu 76 lt ORR or HE gt
99. FDG 4 a FDG 1 2D 185 444MBq 3 7MBq kg 3D 2 5MBq kg FDG b 45 60 E 111 259MBq Z PET PET CT CT PET CT c FDG BERE LTH
100. GT FDG FDG 60 50 75 g 1 120 150 mg dl REO RH eR THEA ICIS MEJ 130 mg dl 1 130 140 mg dl 1 HB 140 160 mg dl 2 160 180 mg dl 3 Hf 180 200 mg dl 5 FDG ACC AHA ASNC L2 FDG 9 5 FDG FDG
101. MRI Tr MRI JIS Z 4951 2012 MRI Lx 9 gt H H Y 89 1 MRI 2 0 5mT 3 MRI 4 MRI
102. a pi n mop FDG PET a 7 AN FDG
103. 40 60 FDG 83 FDG QMRI PET 3D T1 T2 FLAIR T1 T2 2D 3D 3 MRI MR spectroscopy MRS WI DWI 78 9
104. MRI JIRA MR 2 Biograph mMR MR 2006 11 15 Rev 1 1 http www jsrt or jp 071113jsrt jira wg 071113jsrt jira wg 05 pdf 87 1 20m 1 20m MRI 1 PET MRI 1 Biograph mMR Disturbing influences on the magnetic field Static E g iron girders reinforceme
105. PRI tik I i IN FDG FDG PET 2 1 PET FDG PET CT 2009 5 PET PET BU SRE FDG PET 2005 6 AR alii ZEE 1 http www mhlw go jp stf shingi 2r9852000001hx9n att 2r9852000001hxf2 pdf 2 http
106. subclinical 6 1 Drzezga A et al 18F FDG PET studies in patients with extratemporal and temporal T fx Y epilepsy evaluation of an observer independent analysis J Nucl Med 1999 May 40 5 737 46 2 Kim YK et al 18F FDG PET in localization of frontal lobe epilepsy comparison of visual and SPM analysis J Nucl Med 2002 Sep 43 9 1167 74 3 Savic I et al Comparison of 11C flumazenil and 18FIFDG as PET markers of epileptic foci J Neurol Neurosurg Psychiatry 1993 Jun 56 6 615 21 4 Sasaki M et al Carbon 11 methionine PET in focal cortical dysplasia A comparison with fluorine 18 FDG PET and technetium 99m ECD SPECT J Nucl Med 1998 39 6 974 977 Jan 43 1 21 6 2 1 H 2 FDG PET
107. 6 m uH M i 90 7 5 6 80 11 1 2 8 Ma ed DUE Leld Si 80 11 1 3 9 PET MRI 80 16 o JIS Z 4951 2012 MRI
108. C E MR D MR E F
109. 2011 7 PET CT 2009 8 8T MRI 2010 30 222 229 9 Tateishi U et al Bone and soft tissuesarcoma preoperative staging with fluorine 18 fluorodeoxyglucose PET CT and conventional imaging Radiology 2007 245 839 847 wv S li ON ui ng TE nj 10 Drzezga A et al Firstclinicalexperience with integrated whole body PET MR comparison to PET CT in patients with oncologic diagnoses J Nucl Med 2012 53 845 855 11 Buchbender C et al OncologicPET MRI Part 2 Bone Tumors Soft Tissue Tumors Melanoma and Lymphoma J Nucl Med 2012 53 1244 1252 12 Benz MR et al FDG PET CT imaging predicts histopathologic treatment responses after the initial cycle of neoa
110. MRI T2 1 3 MRI PET MRI 4 1 FDG PET PET CT 2010 2012 http www jsnm org files pdf guideline fdg pet guideline 2010 130510 pdf JE
111. 2 Weber OM et al Whole heart steadystate free precession coronary artery magnetic resonance angiography Magn Reson Med 2003j50 1223 1228 3 Sakuma H et al Detection of coronary artery stenosis with whole heart coronary magnetic resonance angiography J Am Coll Cardiol 2006 48 1946 1950 4 Schwitter J et al MR IMPACT comparison of perfusion cardiac magnetic resonance with single photon emission computed tomography for the detection of coronary artery disease in a multicentre multivendor randomized trial Eur Heart J 2008 29 480 489 5 Okumura W et al Usefulness of fasting 18F FDG PET in identification of cardiac sarcoidosis J Nucl Med 2004 45 1989 1998 6 Koiwa H et al Images in cardiovascular medicine imaging of cardiac sarcoid lesions using fasting cardiac 18F fluorodeoxyglucose positron emission tomography an autopsy case Circulation 2010j122 535 536 7 Ohira H et al Myocardial imaging with 18F fluoro 2 deoxyglucose positron emission 27 tomography and magnetic resonance imaging in sarcoidosis Eur J Nucl Med Mol Imaging 2008 35 933 941 8 SCMR MRI 1 0 http scmr jp mri pdf scmr protocols 2007 jp pdf 9 2009 MEUS 2010 htt
112. EL SUTRA fis he Sci L Staging laparotomy staging second look surgery PET CT PET CT 04 A r9 MRI PET MRI BOSA AIE ko CHIMICA lt RBH D lt Eb 1012 DL EOM 2S yf OF eM MRI H PET MRI om ER 2 OFDG 2D 185 444MBq 3 7MBq kg 3D
113. 60 CT FDG 30 5 FDG FDG FDG FDG
114. in ml FYB PET US e Br PET NT ac E da T aN 1 PRT PET PET 5 PET 2 PRT
115. 1 Hae 8 8 1 19 5 18F PET 1 18F 2 PET pu ALL E KK amp H 1 13 d 4 uz fa EO E M F 16 3 25 7
116. 6 PR or SD 1 Weiler Sagie M et al 18F FDG avidity in lymphoma readdressed A study of 766 patients J Nucl Med 51 1 25 30 2010 2 3 FES PET CT 2009 3 Wirth A et al Impact of 18 F fluorodeoxyglucose positron emission tomography on 44 staging and management of early stage follicular non Hodgkin lymphoma Int J Radiat Oncol Biol Phys 71 1 213 9 2008 4 Juweid ME et al Use of positron emission tomography for response assessment of lymphoma consensus of the imaging subcommittee of international harmonization project in lymphoma J Clin Oncol 25 5 571 8 2007 5 Cheson BD et al Revised response criteria for malignant lymphoma J Clin Oncol 25 5 579 86 2007 6 Barrington SF et al Concordance between four European centres of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphioma Eur J Nucl Med Mol Imaging 2010 37 1824 33 7 PET CT 2010 3 1 3 1
117. b 60 kl c P d 11 PET 1 FDG PET 2005 E 42 2 1 26 2005 2 FDG PET 2 42 1 22 2005 8 FDG PET
118. G penetration panel 5 E E W mmi mU o mu fag Ratt S D MRIS m TY hod eH lt oN J MRI
119. PET T 3 4 PET 38 PR 3 FDG XAS ESC PET X FDG PET E
120. 4 MRI IT E g JJ FH RITA H aN HEE ALi EC MRIJ MRI E rS OR FN Ei E t E E RI
121. p 4 1 1 2 3
122. EE PA 31 PET MRI 2 phased array coil endorectal coil T2 thin section MRI 0 6 X0 6mm 3mm 3
123. 16 correlation Am J Roentgenol 2008 191 598 603 3 Scott AM et al PET changes management and improves prognostic stratification in patients with head and neck cancer results of a multicenter prospective study J Nucl Med 2008 49 1593 1600 4 Strobel K et al Head and neck squamous cell carcinoma HNSCC detection of synchronous primaries with 18 F FDG PET CT Eur J Nucl Med Mol Imaging 2009 36 919 927 5 Weber WA et al Monitoring chemotherapy and radiotherapy of solid tumors Eur J Nucl Med Mol Imaging 2006 33 8277 837 6 Nakamoto Y et al Clinical value of image fusion from MR and PET in patients with head and neck cancer Mol Imaging Biol 2009 11 46 53 7 2 2011 8 Thoeny HC et al Diffusion weighted MR imaging in the head and neck Radiology 2012 263 19 32 9 Nakamoto Y et al Normal FDG distribution patterns in the head and neck PET CT evaluation Radiology 2005 234 879 885 10 Nakamura S et al 18F Fluolodeoxyglucose PET CT differentiation between H physiological and pathological accumulations in head and neck Nucl Med Commun 2009 30 498 503 11 Cohade C et al Uptake in supraclavicular area fat USA Fat description on 18F FDG PET CT J Nucl Med 2003 44 170 176 3 3 3 3 1 1 FDG
124. 3 OPET 4 1 FDG PET PET CT 2010 2012 http www jsnm org files pdf guideline fdg pet guideline 2010 130510 pdf 2 3 2000 3 3 2002 4 A La 2012 5 18F FDG PET Radioisotopes 2008 57 15 25 6
125. D CT PET PET CT PET PET CT 24 FDG PET CT MRI CT MRI PET FDG PET 9 FDG PET 8 100 9 PET MRI MRI PET
126. MR HEL 3 8 BE To 4 5 To 1
127. 4 ZEL PET MRI MRI RECIST RECIST1 1 19 3 PET SUV Wahl SUL E EORTC PET study group SUV PET Response Criteria in Solid Tumors PERCIST 2345 V 1 4 1 FDG PET PET CT http www jsnm org files pdf guideline fdg pet guideline 2010 130510 pdf 2
128. STIR T2 T1 Dark blood T1 in out of phase 3 MRI OCT MM MRI Dark blood flow artifact artifact 20 A 1 Inaoka T et al Thymic hyperplasia and thymus gland tumors differentiation with chemical shift MR imaging Radiology 2007 243 869 876 2 Sadohara J et al Thymic epithelial tumors comparison of CT and MR imaging findings of low risk thymomas high risk thymomas and thymic carcinomas Eur J Radiol 2006 60 70 79 3 Takahashi K et al Computed tomo
129. 84 100 HAS RR CHEM TED Seas i Wain ER OR 2317 XS THE T 74 83 MRI OA CLS FDG PET MRI MRI PET CD EET THE di cri 5 FDG PET MRI functional MRI NM EJ
130. A 1 Yamamuro M et al Morphologic and functional imaging of malignant pleural mesothelioma Eur J Radiol 2007 64 356 366 Helm EJ et al Imaging of the pleura J Magn Reson Imaging 2010 32 1275 1286 IW Li ul 2 Gill RR et al Diffusion weighted MRI of malignant pleural mesothelioma preliminary assessment of apparent diffusion coefficient in histologic subtypes AJR Am J Roentgenol 2010 195 W125 130 3 Plathow C et al Therapy response in malignant pleural mesothelioma role of MRI using RECIST modified RECIST and volumetric approaches in comparison with CT Eur Radiol 2008 18 1635 1643 4 Giesel FL et al Dynamic contrast enhanced MRI of malignant pleural mesothelioma a feasibility study of noninvasive assessment therapeutic follow up and possible predictor of improved outcome Chest 2006 129 1570 1576 5 Gerbaudo VH et al FDG PET CT patterns of treatment failure of malignant pleural mesothelioma relationship to histologic type treatment algorithm and survival Eur J Nucl Med Mol Imaging 2011 38 810 821 6 Schaefer NG et al Continued pemetrexed and platin based chemotherapy in patients with malignant pleural mesothelioma MPM value of 18F FDG PET CT Eur J Radiol 2012 81 e19 25 7
131. ATI id P T D 7 ZBL hj Q Bo
132. 2 MRI v 94 P Xr wo P o 1 2 3 2n HE 5 6 FB 4
133. 3 MRI PRT MRI 1 1 2
134. 2 A EL 83 B 1 4 H
135. Hal 0 WU St WE E 1 95 1 FDG PET 2 005 E 2005 2 JIS Z 4951 2012 H HZ Z rd Et EKER UEA E 96 n HE H 42 9 1 26 Bs 2012
136. 2 Pucar D et al Prostate cancer correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy initial experience Radiology 2005 236 545 553 34 3 Mueller Lisse UG et al Localized prostate cancer effect of hormone deprivation therapy measured by using combined three dimensional 1H MR spectroscopy and MR imaging clinicopathologic case controlled study Radiology 2001 221 380 390 4 Majhail NS et al F 18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma J Clin Oncol 2003 21 3995 4000 5 Shreve PD et al Metastatic prostate cancer initial findings of PET with 2 deoxy 2 F 18 fluoro D glucose Radiology 1996 199 751 756 6 Minamimoto R et al Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET contrast enhanced CT Clinical nuclear medicine 2010 35 918 923 7 Avril N et al The clinical advances of fluorine 2 D deoxyglucose positron emission tomography computed tomography in urological cancers Int J Urol 2010 17 6 501 11 8 Powles T et al Molecular positron emission tomography and PET CT imaging in urological malignancies Eur Urol 2007 51 1511 1520 9 Kang DE et al Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma J Urol 2004 171 1806 1809 10 Aide N et al Efficiency of 18 F FDG PE
137. 3 4 1 2 3 2 MRI JIS T1022 1 MRI 2 MRI 3 ZAHI 4 MRI 5 6
138. EO o TADARAK BY CLR E TO CH RAMA FUCK FDG FDG 4 R a FDG 2D 185 444MBq 3 7MBq kg 3D 111 259MBq 2 5MBq kg FDG 1 b A EAE EAH RE FDG 40 60 PET 3D 185MBq 10 2D 370MBq 10 c
139. PET MRI MRI PET MRI QUEE AA CDM Heer Mae E PET 2 52 3 FDG PET 2 9 FDG PET 9 4 FDG
140. or EE 2 ZW I 1 1 28 7 1 83 20 4 WAN m E 1 47 2 22 4 1 190
141. 39 PET MRI 11 919 6 XE CIC o CHRB SH Ef FDG 7 1 FDG PET PET CT 2010 2012 http w
142. PET f PET 7 X 14 x A dE A H pera 1 1 mSv E 50 50 F 20 mSv CALE 1 X Br bT 0 0f
143. FDG PET MRA PET MRI 3 FDG 9 FDG D PET MRI FDG MRI
144. MRI PET MRI 9 MRI 90 65 100 90 5 94 75 100 919 DS PET PET MRI PET BAM PET MRI oj E 6 ES Str hea E Bi
145. MRI Ver 1 0 H 2010 2012 MRI http www jabcs jp images mri guideline fix pdf 3 Buchbender C et al Oncologic PET MRI Part 2 Bone Tumors Soft Tissue Tumors Melanoma and Lymphoma J Nucl Med 53 1244 52 2012 4 54 PET update 1426 1484 2009 24 5 Walter C et al Clinical and diagnostic value of preoperative MRmammography and FDG PET in suspicious breast lesions EurRadiol 13 1651 1656 2003 6 Rieber A et al Pre operative staging of invasive breastcancer with MR mammography and or FDG PET boon or bunk Br J Radiol 75 789 798 2002 7 Heinsich M et al Comparison of FDG PET and dynamic contrast enhanced MRI in the evaluation of suggestivebreast lesions Breast 12 17 22 2003 8 Tateishi U et al Neoadjuvant chemotherapy in breast cancer prediction of pathologic response with PET CT and dynamic contrast enhanced MR imaging prospective assessment Radiology263 53 63 2012 9 Peters NH et al Meta analysis of MR Imaging in the Diagnosis of Breast Lesions Radiology Radiology 246 116 124 2008 10 Harnan SE et al Magne
146. hl 5 4 i FISD MR MRI 71 H Ws 1 BER MRT
147. 2 3 69 H 3 1 F 3 17 4 1 E E ERATES ES 1
148. 28 T1 2D dual echo gradient echo GRE in phase opposed phase SE T2 9 MRI 3 1 Buchbender C et al Oncologic PET MRI part 1 tumors of the brain head and neck chest abdomen and pelvis J Nucl Med 2012 53 928 938 2 Drzezga A et al First clinical experience with integrated whole body PET MR comparison to PET CT in patients with oncologic diagnoses J Nucl Med 2012 53 845 855 3 Schwenzer NF et al Whole body MR PET applications in abdominal imaging Abdom Imaging 2012 37 20 28 4 Donati OF et al Value of retrospective fusion of PET and MR images in detection of hepatic metastases comparison with 18F FDG PET CT and Gd EOB DTPA enhanced MRI J Nucl Med 2010 51 692 699 5 Schreiter NF et al Evaluation of the potential of PET MRI fusion for detection of liver metastases in patients with neuroendocrine tumours Eur Radiol 2012 22 458 467 6 3TMRI 2010 30 190 197
149. AD PER RBH PET CT nu 9 9 M PET CT PET CT 9 PET CT XU CARE HIF EE SEES OJJ B2 CT CE REGES OER N BrB M PET MRI MRI PET CT uu PET CT N PET CT SUV
150. 4
151. PET 91 4 PET MRI PET PET MRI R74 vw 1 2 1 PET MRI 2 3
152. RG BG 75 MRI FDG PET MRI Ko cdi FDG PET 3 Ej MRI functional MRI 2 PET l E 87 71 tumor free margin functional MRI MRI i2
153. 60 2 delay 2 MRI PET MRI Dixon MRI PET MR transmission STIR T2 TI FO DB Dark blood STIR uil 18
154. PET CT PET MRI i 1 ES E R us imi ns 5 i EREA C do BAC LIU VT REPE e SIC PHA E e 2 iine MRI Ia Atypic
155. 3 ARG d FDG K1 4 4 5 ARG 120 mg dl FDG 40 1
156. 30 14 2 1 H DE 5 TBq E 3 NH E 57 s 1 sJ HO 30 11 1 DES E DX 4 8 bul Grp iE 6 FDG PET RECHO CUTE HGH HERES BURY cov CH HE
157. 4 V 5 2 6 PET MRI 7 PET PET PET MBq PET MRI PET 8 PET MRI
158. FDG PET Id 1 HSN SME EDS BAT C SPRCT FDG PET 3 Vite kT RR GRAAL E 1
159. MRI susceptibility CT PET MRI CT MRI CT 2 OFDG PET PET CT 3D UT 111 259MBq 2 5MBq FDG MRI RI Gd DTPA H 0 2ml kg D DCE ORRE 1 PET PET OCT FDG
160. T1 HERAS 9 Diffusion I HSV ILE Perfusion WI PWI w ali 4 1 Yokoi K et al Detection of brain metastasis in potentially operable non small cell lung cancer a comparison of CT and MRI Chest 1999 115 714 719 2 Kr ger S et al Brain metastasis in lung cancer comparison of cerebral MRI and 18F FDG PET CT for diagnosis in the initial staging Nuklearmedizin 14 2011 50 101 106 3 Horky LL et al Dual phase FDG PET imaging of brain metastases provides superior assessment of recurrence versus post treatment necrosis J Neurooncol 2011 103 137 146 4 Kwee SA et al Solitary brain lesions enhancing at MR imaging evaluation with fluorine 18 fluorocholine PET Radiology 2007 244 557 565 5 Morita N et al Clinical application of MR spectroscopy and imaging of brain tumor Magn Reson Med Sci 2010 9 167 175 6 Poptani H et al Characterization of intracranial mass lesions with in vivo proton MR spectroscopy AJNR 1995 16 1593 1603 7 Gerstner ER et al Diffusion and diffusion tensor ima
161. E 30 26 1 FDG PET 8 3 30 11 1 3 H E F 30 26 1
162. FDG PET ix CT MRI CT MRI PET MRI MRI PET FDG PET MRI 2 2 60 MR PET MRI MRI 3 SH e T1 3D thin sli
163. MR spectroscopy functional imaging MRI PET PET PET NT T 38
164. 2 mSv 3 75 E 1 mSv 5 2 4 FDG FDG D FDG 2 3 4 5 FDG FDG FDG E
165. FDG XE Fie FDG 10 PET PET 10 1 ER 7 FEL HE E
166. FER TAX GERI L L TITA BRERSEJU ORKA B multifocal 6 avidity MRI Cheson reference L SUV 2 H ADC PET MRI
167. T1 8D thin slice c T1 d 1 T2 T2 ADC Apparent diffusion coefficient FDG PET MRS FDG PET FF PET MRI 295 3 FDG
168. aN 3 FDG PET 49 OBE 4 b FDG PET FDG FDG FDG PET iue O 6 FDG PET 7 8 FDG PET 2 FDG PET PET FDG PET E
169. 2 a TARA OW b DO JAF H gt ff Qr 3A nz 5 1 BCE YA d e 1 X g ET ii TES
170. 3 PET MRI 1 PET PET FDG PET 2005 FDG PET 2 24 6 1 JIS Z 4951 2012 2 JIS Z 4951 2012 MRI 3 PET MRI MRI PET 1 2 PET MRI
171. 9 FDG 10 PET FDG SAR WE FDG aN FDG PET FDG PET 16 8
172. MRI 5 MRI 1 3 PET MRTI PET MRTI 80 8 2 PET MRI MRI MRI PET MRI MRI
173. 111 259MBq 2 5MBq kg FDG i 60 MRI 8g T1 coT2 3 3 Hee JEE thin slice 1 o PET CT E EET a T2 PET MRI E PET MRI Ib ay x PET CT
174. 13 MRI 3 WE 77 LEC 3 IE WIE 63 2 2 3 XR RoR ox EE JE NS H i ES ad UU OF og E c 0o 10 oO A 10 11 12 13 H 15 16 17 18 19
175. 3 1 pom panj 2 3 E 3 4 EEF BATAI db v EX MRI
176. E E B3 Kangarlu A and Robitaille PML Biological effects and health implications in magnetic resonance imaging Concepts in Magnetic Resonance 12 321 359 2000 Guidance for industry and FDA staff Criteria for significant risk investigations of magnetic resonance diagnostic devices U S Department of Health and Human 85 Services Food and Drug Administration Center for Devices and Radiological Health July 14 2003 Kanal E et al American College of Radiology White Paper on MR Safety 2004 update and revisions AJR Am J Roentgenol 182 1111 1114 2004 Shellock FG et al MR procedures biologic effects safety and patient care Radiology 232 635 652 2004 Gowland PA et al eds Special issue MR safety J Magnetic Resonance Imaging 26 Number 5 2007 Shellock FG The reference manual for magnetic resonance safety implants and devices 2008 eds Biomedical Research Publishing Group Los Angeles 2008 86 4 PET MRI MRI TA act Cc RF Ay T E
177. GEAR LTEM REGERE ERBO CURAE HH e EHE T BOWE T E PRAAMIL POMC BA edo TSE 2006 11 10 if AGES ORED A CA e R
178. H S T A HI M CBE Zp ED 518 2 4 MA BIE Bey 1 RER E ne L E E 2 d 42 RTE LIC LAB OME ZL
179. PET PET CT PET MRI PET CT MRI OMRI Pancoast 23 STIR short inversion time inversion recovery viability 9 9 10 MRI FDG PET PETUCT mee 17
180. 1 22 PET CT 4 PET 24 4 MRI PET oim FDG 18 4 IZ PET EE EB IR 9 ES PET MRI 24 PET MRI
181. I aN So Ca a MRI lt q MP 1 A MRI MRI B MRI
182. MRI Society of Cardiovascular Magnetic Resonance SCMR 9 MRI PET PET 9 FDG PET 24 50IU kg 15 FDG 60 A 1 Kim WY et al Coronary magnetic resonance angiography for the detection of coronary stenoses N Eng J Med 2001 345 1863 1869 uj ul
183. 1 H 2 a b E in P F H D ITA ESEN C n PET PET CT PET MRI 3 JIO E FDG TFDG PET CT MRI S A Ja a AREIS M RB
184. 2 FDG PET 5 1 FDG PET BON 2 FDG 3 FDG E 4 FDG PET 5 6 FDG PET 5 1 FDG PET FDG
185. EB FDG RAS 2 F 407 50 nSv hr 80 100 nSv hr 5 10 pSwhr
186. MRI 8 T1 thin slice c T1 iy FDG PET d T1 MRS ib FDG PET dde BSA Ma yy cwm 5
187. e id E RS PET 4 EL CW AB HEL CVA Ay e 4 E 9B HU ER ah 2o 5 6 1 A L 5 SE gt
188. PET PET PET PET MRI PET MRI PET PET 3 1 1 4 PET MRI PET MRI 5 80 8 2
189. uptake 13N jin GE 2 FDG PET FDG PET FDG PET PET PET PET ay Si Usc CLARA CRIBB T D L EOE PET 1 13N 82Rb 2 99mTc SPECT 201T
190. 12 28 AB 1 1 2 SIS 3 4 n seca hee iuh v cu am 5 10 2 10 1 1 28 1
191. ERE 4 Cheson FDG PET Off Ne SHEMET SS RIB EB ip PET MRI PET BELT avidity 3 PET MRI 4 OFDG T ui Iz I j 2007 avidity DLBCL 2 ET 1 79 ETER KA
192. PET vog 12 Wirth 42 FDG PET 3 FDG PET 9796 38 37 95 CI 86 100 3 cix TII 12 TI avidity International Workshop Response Criteria FDG PET Juweid aggressive TS E 19 45 95 CI 30 61 EE 19 17 40 upstage 18 Vii 1 FDG PET BAR E Har
193. ne EW MERC FDG PET MRI 90 52 100 72 17 FDG PET PET Hf EA MRI 4 100 PET 63 20 100 o AAA H RB EDU Wan pi 1 2 1 TEOR
194. 10 12 mm 6 PET CT PET MRI E iH ih Br e T2 387 T2 ADC ioo FDG PET PET MRI gt 2 MRI 8D R HKEE Ze ZH C Made MRS FDG PET OJIRE SABO E PRAE FE UEBER ORC jv ED WRH E T gt DEA AZ C52 El 2326 lt amp AD D CA EROAREA B lt E EEES MERE NEA RERE O CERE L 72 5 CT
195. 2 SARI SAR RF gt BY 180 BeOS WEED MRI RE SAR Specific absorption rate 3
196. T2 3 MRI PET MRI 4 1 FDG PET PET CT 2010 2012 http www jsnm org files pdf guideline fdg pet guideline 2010 130510 pdf 2 Al Sukhmi E et al Diagnostic accuracy of MRI for assessment of T category lymph node metastases and circumferential resection margin involvement in patients with rectal cancer a systematic review and meta analysis Ann Surg Oncol 2012 19 2212 2223 3 Kim DJ et al Nodal staging of rectal cancer high resolution pelvic MRI versus 1 8 F FDGPET CT J Compt Assist Tomogr 2011 35 531 534 4 Lambregts DM et al Value of MRI and diffusion weighted MRI for the diagnosis of locally recurrent rectal cancer Eur Radiol 2011 21 1250 1258 5 Moore HG et al A
197. 1 PET PET 2005 D 10 PET EDG PET PET MRI 1 FDG PET 2 FDG PET 3 FDG 4 PET 5 6 7 FDG PET 8
198. T2 T2 PRET T2 E ul 38 3 point Dixon interactive decomposition of water and fat with echo asymmetry and least squares estimation IDEAL MR PET
199. WB j c f1 a OX Tp TAR 72 PICK 5 ZEE SPWERZR UOT D POR A i FoU E GE 24 4 dg 2 h 24 4 E 4 FE 4 E PURER T LIER UT RATZ Uv WUREROOBIRLOS
200. FDG PET 1 2 3 4 5 6 50 7 2 2 D 18F 8 4 PET PET V 1 FDG PET DIED X 3 H EO XE AVND FC
201. 3 6 2 2 BRM IEE E 1 MRI T2 JMagnetic resonance cholangiopancreatography MRCP 29 PET MRI PET CT 9 2 MRI 3 MRCP 3 1 Sacks A et al Value of PET CT in the management of primary hepatobiliary tumors part 2 AJR Am J Roentgenol 2011 197 W260 265 2 Chung YE et al Staging of extrahepatic cholangiocarcinoma Eur Radiol 2008 18 2182 2195 3 Catalano OA et al MR imaging of the gallbladder a pictorial essay Radiographics 2008 28 135 155 JW au 29 3 6 2 3 PER MENOR PEAREN WEA C 1
202. 5 HOD zz Laj H 7 2 FDG SL AIC BLE SIV Cv VT Ec 1 1 mSv 2 3 4 3 7 9 PET 3 ABEX i C BO ORE Ty 1 4 H
203. 5 4 5 7 E T 1 amp 1mSy 8 2 30 11 1 2
204. Lane FDG DIT QFDG 5 SUV standardized uptake value SUV 1 00 SUV Xx
205. N ROJE Br 1 E i E EHE E 3 BS aS E 4 1 E Ene 2
206. Ne 3 PET MRI PET MRI MRI 3 1 FDG PET FDG PET FDG PET 1 FDG PET 2 FDG 3 4 FDG PET 3 2 MRI MRI 2 MRI MR J
207. PURE ORIL lt RR 2007 5 FDG 15 10 5 1 i 0 011 0 014 0 022 0 032 0 061 0 160 0 210 0 280 0 320 0 590 0 019 0 025 0 036 0 050 0 095 FDG PET KU PET 2 2 2 MIRD 5 2 5 2 1 FDG PET PET FDG
208. 26 FDG PRT FDG Eit f Br UC UCATEBE2S jo 5 Tv D PET MRI 2 MRIS EO PET MRI PET 4 PET MRI
209. 27 425 56 2007 4 1CRP Publication 80 1998 49 5 FDG PET 44 4 1 28 2007 6 National Council on Radiation Protection and Measurements Limitations of X exposure to ionizing radiation National Council on Radiation Protection andMeasurements NCRP Report No 116 1993 7 Medical and Dental Guidance Notes A good practice guide on all aspects of lonizingradiation protection in the clinical environment IPEM 2002 61 2 MRI PET MRI PRT CT ST MR MR PET MRI MR MR 1 9 MR 2JRE radio frequency 3
210. 9 TFDG PET PET MRI MRI PRET MRI PET MRI 9 MRI CT N 15 BESRA ESHEBU DSO RPMI 5 MRI
211. case controlled study of 18 fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients J Am Coll Surg 2003 1977 22 28 6 Gu J et al Dynamic contrast enhanced MRI of primary rectal cancer quantitative 32 correlation with positron emission tomography computed tomography Journal of magnetic resonance imaging JMRI 2011 33 340 347 7 Park MJ et al Locally advanced rectal cancer added value of diffusion weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy Radiology 2011 260 771 780 8 Kam MH et al Comparison of magnetic resonance imaging fluorodeoxy glucose positron emission tomography fusion with pathological staging in rectal cancer Br J Surg 2010 97 266 268 9 Vliegen RF et al Can an FDG PET CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer Strahlentherapie und Onkologie 2008 184 45 7 464 10 Wieder HA et al Rectal cancer MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor free circumferential resection margins and long term survival Radiology 2007 243 744 751 Tx BEM WUBORR EDOT PIIRAA COW Ras EO IL RKO ROERNE PET
212. detection with integrated FDG PET CT Radiology 238 272 279 2006 7 Choi HJ et al Comparison of the accuracy of magnetic resonance imaging and positron emission tomography computed tomography in the presurgical detection of 37 lymph node metastases in patients with uterine cervical carcinoma a prospective study Cancer 15 914 922 2006 8 3 10 1 PET CT 2009 FDG PET 18F Fluoro 2 Deoxy D Glucose FDG PET CT T PET MRI DoD PET MRI
213. e mRum ssmxemomm o EE xwmir e D el Deve esr Se DE b c d SMPTE 80 2 xm hh TT was 9 asme sso o emaom wea O O mewxumows mg O 2 a rme o 9 4 8 b HE WADA c d e 10 a d O O O Q l TE Joj b Lo p Smemowe e S O 5
214. melanoma patients comparison of 18F FDG PET CT CT brain MRI and tumor marker S 100B Eur J Nucl Med Mol Imaging 2008 35 1786 1795 7 Muller Horvat C et al Prospective comparison of the impact on treatment decisions of whole body magnetic resonance imaging and computed tomography in patients with 41 metastatic malignant melanoma Eur JCancer 2006 42 342 350 8 Pfannenberg C et al Prospective comparison of 18F fluorodeoxyglucose positron emission tomography computed tomography and whole body magnetic resonance imaging in staging of advanced malignant melanoma Eur J Cancer 2007 43 557 564 9 Laurent V et al Comparative study of two whole body imaging techniques in the case of melanoma metastases advantages of multi contrast MRI examination including a diffusionweighted sequence in comparison with PET CT Eur J Radiol 2010 75 3776 383 3 12 say 2 il Design Decus 2 2 2 2 3 1 0 2 3 2 FADS BEL CK YI Ji 7g OO 2 Ze SER H SX EK HIE 4 vi 1
215. urography PET 90 AN IZ ES Clk T2 MR spectroscopy endorectal coil T2 PET MRI
216. 0 E 2010 47 158 162 2 Martinez Moller A et al Workflow and Scan Protocol Considerations for Integrated Whole Body PET MRI in Oncology J Nucl Med 2012 Aug 9 Epub ahead of print 3 6 2 3 6 2 1 WER CFA ALCS ER ERE C 1 MRI 19 PET PET MRI PET MRI PET CT 1 9 OTS PET MRI PET MRI 1 2 MRI
217. FDG PET MRI 2012 Ver 1 0 1 SF 2 GH ne PET MRI WEER JEER MIRJE FERREE MEE PREE JEA iD MEETS fe N A IMRE JERI ERA AOE PRL ANA RRS FEK FHER
218. Francis RJ et al Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3 dimensional volume based analysis of serial 18F FDG PET scans J Nucl Med 2007 48 1449 1458 8 Veit Haibach P et al Combined FDG PET CT in response evaluation of malignant pleural mesothelioma Lung Cancer 2010 67 311 317 9 Basu S et al Current evidence base of FDG PET CT imaging in the clinical management of malignant pleural mesothelioma emerging significance of image segmentation and global disease assessment Mol Imaging Biol 2011 13 801 811 10 Lee ST et al Prognostic value of 18F FDG PET CT in patients with malignant pleural mesothelioma Mol Imaging Biol 2009j11 473 479 11 MaviA et al Potential of dual time point FDG PET imaging in differentiating malignant from benign pleural disease Mol Imaging Biol 2009 11 369 378 3 4 22 1 FDG 21 100
219. T in characterising renal cancer and detecting distant metastases a comparison with CT Eur J Nucl Med Mol Imaging 2003 30 1236 1245 11 Heicappell R Muller Mattheis V Reinhardt M Vosberg H Gerharz CD Muller Gartner H et al Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2 18 F 2 deoxy D glucose Eur Urol 1999 36 582 587 12 Ahlstrom H et al Positron emission tomography in the diagnosis and staging of urinary bladder cancer Acta Radiol 1996 37 180 185 13 Outwater EK et al Lipid in renal clear cell carcinoma detection on opposed phase gradient echo MR images Radiology 1997 205 103 137 14 Zhang J et al Imaging of bladder cancer Radiol Clin North Am 2007 45 183 205 3 9 1 FDG PET DINKA 35 JELLO FR HER DOCU second reductive surgery QT E STR m v
220. TS Z 4951 20122 1 2 3 4 5 MRI 3 3 PET MRI E 4p Ed PET MRI 3 1 FDG PET 3 2 JIS Z 4951 2012 MRI
221. XE 2 FDG PET 3 4 A X PET ES EL ADAE JE AS
222. al polypoid adenomyoma APAM 4 1 Sironi S et al Intergrated FDG PET CT in patients with ovarian cancer correlation with histopathologic findings Radiology 233 433 440 2004 2 Chung HH et al Role of 18F FDG PET CT in the assessment of suspected recurrent ovarian cancer correlation with clinical or histological findings Eur J Nucl Med Mol Imaging 34 480 486 2007 3 Castellucci P et al Diagnostic accuracy of 18F FDG PET CT in characterizing ovarian lesions and staging ovarian cancer correlation and transvaginal ultrasonography computed tomography and histology Nucl Med Commun 28 589 595 2007 4 Horowitz NS et al Prospective evaluation of FDG PET for detecting pelvic and para aortic lymph node metastasis in uterine corpus cancer Gynecol Oncol 95 546 551 2004 5 Chao S et al 18F FDG PET in the management of endometrial cancer Eur J Nucl Med Mol Imaging 33 36 44 2006 6 Sironi S et al Lymph node metastases in patients with clinical early stage cervical cancer
223. ce d T2 PET MRI 3 I xS nu 45
224. djuvant chemotherapy in high grade soft tissue sarcomas Clin Cancer Res 2009 15 2856 2863 13 Herrmann K et al 18F FDG PET CT Imaging as an early survival predictor in patients with primary high grade soft tissue sarcomas undergoing neoadjuvant therapy 39 Clin Cancer Res 2012 18 2024 2031 14 Delso G et al Performance measurements of the Siemens mMR integrated whole body PET MR scanner J Nucl Med 2011 52 1914 1922 15 Fuglo HM et al The diagnostic and prognosticvalue of 18 F FDGPET CT in the initial assessment of high grade bone and soft tissue sarcoma A retrospective study of 89 patients Eur J Nucl Med Mol Imaging 2012 39 1416 1424 16 Meyer JS et al Imaging guidelines for children with Ewing sarcoma and osteosarcoma a report from the Children s Oncology Group Bone Tumor Committee Pediatr Blood Cancer 2008 51 163 170 17 Subhawong TK et al Proton MR Spectroscopy in metabolic assessment of musculoskeletal lesions AJR Am J Roentgenol 2012 198 162 72 3 1 1 1 FDG vf 1 m
225. ging in brain cancer Semin Radiat Oncol 2011 21 2 141 146 8 Ellingson B M et al Validation of functional diffusion maps fDMs as a biomarker for human glioma cellularity J Magn Reson Imaging 2010 31 538 548 9 Romano A et al Clinical applications of dynamic susceptibility contrast perfusion weighted MR imaging in brain tumours Radiol Med 2012 117 3 445 460 10 Hayashi S et al Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma Radiat Med 1995 13 4 167 170 3 2 1 EDG TEDG PET CT MRI ee 0 6877 22 ER FAARROBNSESERPECOFDG xo a SEHE OR Pouch adi mE FDG PET 9 FDG PET
226. graphy and magnetic resonance imaging of mediastinal tumors J Magn Reson Imaging 2010 32 1325 1339 4 Inoue A et al 18 F FDG PET for the evaluation of thymic epithelial tumors Correlation with the World Health Organization classification in addition to dual time point imaging Eur J Nucl Med Mol Imaging 2009 36 1219 1225 5 Sung YM et al 18F FDG PET CT of thymic epithelial tumors usefulness for distinguishing and staging tumor subgroups J Nucl Med 2006 47 1628 1634 6 Gumustas S et al Malignant versus benign mediastinal lesions quantitative assessment with diffusion weighted MR imaging Eur Radiol 2011 21 2255 2260 7 Razek AA et al Assessment of mediastinal tumors with diffusion weighted single shot echo planar MRI J Magn Reson Imaging 2009 30 535 540 3 3 3 1 MRI CT 12 9
227. ing Radiology 2008 248 632 642 3 3 2 1 chemical shift imaging MRI 23 FDG PET 49 MRI viability 2 PET MRI PET MRI Dixon ERE Bult
228. ng of non small cell lung cancer of the superior sulcus part 1 anatomy clinical manifestations and management Radiographics 2008 28 551 560 quiz 620 3 Bruzzi JF et al Imaging of non small cell lung cancer of the superior sulcus part 2 initial staging and assessment of resectability and therapeutic response Radiographics 2008 28 561 572 4 Kosucu P et al Mediastinal lymph nodes assessment with diffusion weighted MR imaging J Magn Reson Imaging 2009 30 292 297 5 Morikawa M et al The effectiveness of 18F FDG PET CT combined with STIR MRI for diagnosing nodal involvement in the thorax J Nucl Med 2009 50 81 87 6 Yabuuchi H et al Non small cell lung cancer detection of early response to 19 chemotherapy by using contrast enhanced dynamic and diffusion weighted MR imaging Radiology 2011 261 598 604 7 Matoba M et al Lung carcinoma diffusion weighted mr imaging preliminary evaluation with apparent diffusion coefficient Radiology 2007 243 570 577 8 Kim HY et al Nodal metastasis in non small cell lung cancer accuracy of 3 0 T MR imaging Radiology 2008 246 596 604 9 Ohno Y et al Non small cell lung cancer whole body MR examination for M stage assessment utility for whole body diffusion weighted imaging compared with integrated FDG PET CT Radiology 2008 248 643 654 10 Yi CA et al Non small cell lung cancer staging efficacy comparison of integrated PET CT versus 3 0 T whole body MR imag
229. nts especially beneath the magnet Partially correctable by shimming of the magnet and or compliance with minimum clearances maximum weights E g moving ferromagnetic objects electrica wiring transformers Avoidable when minimum clearances are observed Minimum distance depend on moving direction and magnet orientation If distances are not kept please contact the Planning Department Minimum clearance clearance Max weight Water cooing system Lum jx Wheelchairs up to approx Sog ssm esm Carts up to approx 200 ig som vom Gudeines Tiansiomers lt 1600 KVA om som for minimum High voltage cables 1000 A 120m 50m demanes Cars up io aopo og esm i Cars up to approx 900 kg 80m maximum Tetsuptomppo4500tgbts 7om asm weighs Groton om om Srecan 400m 400m Numi systems with 300m magnetic navigation Reinforcement steel in the floor Near 100 kg m mare cmm This minimum distance is required for shimming Distance for magnetic shielding has to be adjusted according to individual shielding requirements 88 5 PET MRI PET MRI 1 PET 2 MRI
230. p www j circ or jp guideline pdf JCS2010tamaki h pdf DR 3 3 6 HJEK 3 6 1 1 TFDG TFDG PET CT MRI CT MRI 2 MRI Spin echo SE T1 Short tau inversion recovery STIR Single shot SR T2 MRI 2 1 PET FDG PET PET CT 201
231. s Eur Radiol 2012 22 2 439 446 9 Pichler BJ et al PET MRI hybrid imaging devices and initial results Eur Radiol 2008 18 6 1077 1086 10 Boss A et al Hybrid PET MRI of intracranial masses initial experiences and comparison to PET CT J Nucl Med 2010 51 8 1198 1205 11 Boss A et al Feasibility of simultaneous PET MR imaging in the head and upper neck area Eur Radiol 2011 21 7 1439 1446 12 12 Park H et al Introducing parametric fusion PET MRI of primary prostate cancer J Nucl Med 2012 58 4 546 551 13 Buchbender C et al Oncologic PET MRL part 1 tumors of the brain head and neck chest abdomen and pelvis J Nucl Med 2012 53 6 928 938 14 Buchbender C et al Oncologic PET MRI Part 2 Bone Tumors Soft Tissue Tumors Melanoma and Lymphoma J Nucl Med 2012 53 8 1244 1252 13 3 1 1 FDG PET MRI CT PET CT MRI CT 5mm 1 50 97 MRI
232. tic resonance for assessment of axillary lymph node status in early breast cancer a systematic review and meta analysis Eur J Surg Oncol 37 928 36 2011 11 Scaranelo AM et al Accuracy of unenhanced MR imaging in the detection of axillary lymph node metastasis study of reproducibility and reliability Radiology 262 425 34 2012 12 Escalona S et al A systemic revierreview of FDG PET in breast cancer Med Oncol 27 114 129 2010 13 Cooper KL et al Positron emission tomography PET for assessment of axillary lymph node status in early breast cancer systematic review and meta analysis Eur J Surg Oncol 37 187 98 2011 14 Breast imaging reporting and data system BI RADS fourth ed American College ofRadiology http www acr org Reston VA American College of Radiology 2003 15 Eisenhauer EA et al New response evaluation criteria in solid tumours revised RECIST guideline version 1 1 Eur J Cancer45 228 47 2009 16 Young H et al Measurement of clinical and subclinical tumour response using 18F fluorodeoxyglucose and positron emission tomography review and 1999 EORTC recommendations European Organization for Research and Treatment of Cancer EORTC PET Study Group Eur J Cancer 1999 35 1773 1782 17 Wahl RL et al From RECIST to PERCIST Evolving Considerations for PET response criteria in solid tumors J Nucl Med50 Suppl 1 122S 50S 2009 3 5 1
233. ww jsnm org guideline 20100330 2 FDG PET 2 http www jsnm org files pdf guideline fdg_guide2 2 pdf EI LU 3 Hofmann M et al MRI based attenuation correction for PET MRI a novelapproach combining pattern recognition and atlas registration J Nucl Med 2008 49 11 1875 1883 4 Hofmann M et al Towards quantitative PET MRI a review of MR based attenuation correction techniques Eur J Nucl Med Mol Imaging 2009 36 Suppl 1 893 8104 5 Keereman V et al MRI based attenuation correction for PET MRI using ultrashort echo time sequences J Nucl Med 2010 51 5 812 818 6 Pichler BJ et al PET MRI paving the way for the next generation of clinical multimodality imaging applications J Nucl Med 2010 51 3 333 336 7 Malone IB et al Attenuation correction methods suitable for brain imaging with a PET MRI scanner a comparison of tissue atlas and template attenuation map approaches J Nucl Med 2011352 7 1142 1149 8 Dikaios N et al MRI based motion correction of thoracic PET initial comparison of acquisition protocols and correction strategies suitable for simultaneous PET MRI system
234. www mhlw go jp bunya kenkou gan04 index html 3 http www radiology jp modules senmoni index php id 3 4 FDG PET CT http www radiology jp modules news article php storyid 120 5 6 7 8 0801001 0601006 10 FDG PET 2007 vc 0330010 9 PD in in FDG PET 2 42 4 1 22 2005 27 425 56 4 11 FDG PET OT
Download Pdf Manuals
Related Search